Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Liabilities from Discontinued Operations (2021 - 2023)

Historic Liabilities from Discontinued Operations for Insight Molecular Diagnostics (IMDX) over the last 3 years, with Q4 2023 value amounting to $45000.0.

  • Insight Molecular Diagnostics' Liabilities from Discontinued Operations fell 9775.56% to $45000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $45000.0, marking a year-over-year decrease of 9775.56%. This contributed to the annual value of $45000.0 for FY2023, which is 9775.56% down from last year.
  • Latest data reveals that Insight Molecular Diagnostics reported Liabilities from Discontinued Operations of $45000.0 as of Q4 2023, which was down 9775.56% from $90000.0 recorded in Q3 2023.
  • Over the past 5 years, Insight Molecular Diagnostics' Liabilities from Discontinued Operations peaked at $2.0 million during Q4 2022, and registered a low of $45000.0 during Q4 2023.
  • For the 3-year period, Insight Molecular Diagnostics' Liabilities from Discontinued Operations averaged around $760200.0, with its median value being $135000.0 (2023).
  • Per our database at Business Quant, Insight Molecular Diagnostics' Liabilities from Discontinued Operations soared by 3138.93% in 2022 and then crashed by 9775.56% in 2023.
  • Quarter analysis of 3 years shows Insight Molecular Diagnostics' Liabilities from Discontinued Operations stood at $1.5 million in 2021, then surged by 31.39% to $2.0 million in 2022, then plummeted by 97.76% to $45000.0 in 2023.
  • Its last three reported values are $45000.0 in Q4 2023, $90000.0 for Q3 2023, and $135000.0 during Q2 2023.